The kynurenine pathway and neurodegenerative disease

Seminars in Cell and Developmental Biology

Volumn 40, Issue , 2015, Pages 134-141

  Maddison, Daniel C ^a   Giorgini, Flaviano ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Alzheimer's disease; Huntington's disease; KMO; Kynurenine 3 monooxygenase; Kynurenine pathway; Neurodegeneration; Parkinson's disease

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN 2,3 DIOXYGENASE; TRYPTOPHAN;

ALZHEIMER DISEASE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CELL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; IMMUNOREACTIVITY; LIPID PEROXIDATION; MICROGLIA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; REVIEW; ANIMAL; METABOLISM;

EUKARYOTA; MAMMALIA;

ANIMALS; HUMANS; KYNURENINE; METABOLIC NETWORKS AND PATHWAYS; NEURODEGENERATIVE DISEASES; TRYPTOPHAN;

EID: 84929289074     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.03.002     Document Type: Review

References (94)

1. Foster A.C., Whetsell W.O., Bird E.D., Schwarcz R. Quinolinic acid phosphoribosyltransferase in human and rat brain: activity in Huntington's disease and in quinolinate-lesioned rat striatum. Brain Res 1985, 336:207-214.
2. Pucci L., Perozzi S., Cimadamore F., Orsomando G., Raffaelli N. Tissue expression and biochemical characterization of human 2-amino 3-carboxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism. FEBS J 2007, 274:827-840.
3. Stone T.W., Perkins M.N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 1981, 72:411-412.
4. Lapin I.P. Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. J Neural Transm 1978, 42:37-43.
5. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-318.
6. Foster A.C., Collins J.F., Schwarcz R. On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 1983, 22:1331-1342.
7. Whetsell W.O., Schwarcz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci Lett 1989, 97:271-275.
8. Tavares R.G., Tasca C.I., Santos C.E., Alves L.B., Porciuncula L.O., Emanuelli T., et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 2002, 40:621-627.
9. Ting K.K., Brew B.J., Guillemin G.J. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflamm 2009, 6(36). 2094-6-36.
10. Perez-De La Cruz V., Carrillo-Mora P., Santamaria A. Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 2012, 5:1-8.
11. Rios C., Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 1991, 16:1139-1143.
12. Santamaria A., Rios C. MK-801 an N-methyl-d-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci Lett 1993, 159:51-54.
13. Stipek S., Stastny F., Platenik J., Crkovska J., Zima T. The effect of quinolinate on rat brain lipid peroxidation is dependent on iron. Neurochem Int 1997, 30:233-237.
14. Platenik J., Stopka P., Vejrazka M., Stipek S. Quinolinic acid-iron(ii) complexes: slow autoxidation, but enhanced hydroxyl radical production in the Fenton reaction. Free Radic Res 2001, 34:445-459.
15. Braidy N., Grant R., Adams S., Brew B.J., Guillemin G.J. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 2009, 16:77-86.
16. Perez-Severiano F., Escalante B., Rios C. Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity. Neurochem Res 1998, 23:1297-1302.
17. Behan W.M., McDonald M., Darlington L.G., Stone T.W. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 1999, 128:1754-1760.
18. Nakao N., Grasbon-Frodl E.M., Widner H., Brundin P. Antioxidant treatment protects striatal neurons against excitotoxic insults. Neuroscience 1996, 73:185-200.
19. Vazquez S., Garner B., Sheil M.M., Truscott R.J. Characterisation of the major autoxidation products of 3-hydroxykynurenine under physiological conditions. Free Radic Res 2000, 32:11-23.
20. Giles G.I., Collins C.A., Stone T.W., Jacob C. Electrochemical and in vitro evaluation of the redox-properties of kynurenine species. Biochem Biophys Res Commun 2003, 300:719-724.
21. Okuda S., Nishiyama N., Saito H., Katsuki H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci U S A 1996, 93:12553-12558.
22. Okuda S., Nishiyama N., Saito H., Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 1998, 70:299-307.
23. Smith A.J., Smith R.A., Stone T.W. 5-Hydroxyanthranilic acid, a tryptophan metabolite, generates oxidative stress and neuronal death via p38 activation in cultured cerebellar granule neurones. Neurotox Res 2009, 15:303-310.
24. Guidetti P., Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 1999, 11:3857-3863.
25. Goldstein L.E., Leopold M.C., Huang X., Atwood C.S., Saunders A.J., Hartshorn M., et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry 2000, 39:7266-7275.
26. Iwahashi H., Ishii T., Sugata R., Kido R. Superoxide dismutase enhances the formation of hydroxyl radicals in the reaction of 3-hydroxyanthranilic acid with molecular oxygen. Biochem J 1988, 251:893-899.
27. Christen S., Peterhans E., Stocker R. Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc Natl Acad Sci U S A 1990, 87:2506-2510.
28. Leipnitz G., Schumacher C., Dalcin K.B., Scussiato K., Solano A., Funchal C., et al. In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain. Neurochem Int 2007, 50:83-94.
29. Colin-Gonzalez A.L., Maya-Lopez M., Pedraza-Chaverri J., Ali S.F., Chavarria A., Santamaria A. The Janus faces of 3-hydroxykynurenine: dual redox modulatory activity and lack of neurotoxicity in the rat striatum. Brain Res 2014, 1589:1-14.
30. Lugo-Huitron R., Blanco-Ayala T., Ugalde-Muniz P., Carrillo-Mora P., Pedraza-Chaverri J., Silva-Adaya D., et al. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol 2011, 33:538-547.
31. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001, 21:7463-7473.
32. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 1982, 247:184-187.
33. Rafice S.A., Chauhan N., Efimov I., Basran J., Raven E.L. Oxidation of l-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase. Biochem Soc Trans 2009, 37:408-412.
34. Meng B., Wu D., Gu J., Ouyang S., Ding W., Liu Z.J. Structural and functional analyses of human tryptophan 2,3-dioxygenase. Proteins 2014, 82:3210-3216.
35. Ren S., Correia M.A. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase?. Arch Biochem Biophys 2000, 377:195-203.
36. Li J.S., Han Q., Fang J., Rizzi M., James A.A., Li J. Biochemical mechanisms leading to tryptophan 2,3-dioxygenase activation. Arch Insect Biochem Physiol 2007, 64:74-87.
37. Walker A.K., Budac D.P., Bisulco S., Lee A.W., Smith R.A., Beenders B., et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013, 38:1609-1616.
38. Konan K.V., Taylor M.W. Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996, 271:19140-19145.
39. Campbell B.M., Charych E., Lee A.W., Moller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 2014, 8:12.
40. Takikawa O., Kuroiwa T., Yamazaki F., Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 1988, 263:2041-2048.
41. Zunszain P.A., Anacker C., Cattaneo A., Choudhury S., Musaelyan K., Myint A.M., et al. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012, 37:939-949.
42. Connor T.J., Starr N., O'Sullivan J.B., Harkin A. Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?. Neurosci Lett 2008, 441:29-34.
43. Molteni R., Macchi F., Zecchillo C., Dell'agli M., Colombo E., Calabrese F., et al. Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine. Eur Neuropsychopharmacol 2013, 23:1645-1655.
44. Giorgini F., Moller T., Kwan W., Zwilling D., Wacker J.L., Hong S., et al. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem 2008, 283:7390-7400.
45. Guillemin G.J., Smith D.G., Smythe G.A., Armati P.J., Brew B.J. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 2003, 527:105-112.
46. Dang Y., Dale W.E., Brown O.R. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med 2000, 28:615-624.
47. Gal E.M., Sherman A.D. l-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 1980, 5:223-239.
48. Speciale C., Schwarcz R. Uptake of kynurenine into rat brain slices. J Neurochem 1990, 54:156-163.
49. Guillemin G.J., Kerr S.J., Smythe G.A., Smith D.G., Kapoor V., Armati P.J., et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001, 78:842-853.
50. Gramsbergen J.B., Hodgkins P.S., Rassoulpour A., Turski W.A., Guidetti P., Schwarcz R. Brain-specific modulation of kynurenic acid synthesis in the rat. J Neurochem 1997, 69:290-298.
51. Rassoulpour A., Wu H.Q., Poeggeler B., Schwarcz R. Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain. Brain Res 1998, 802:111-118.
52. Speciale C., Schwarcz R. On the production and disposition of quinolinic acid in rat brain and liver slices. J Neurochem 1993, 60:212-218.
53. Heyes M.P., Saito K., Major E.O., Milstien S., Markey S.P., Vickers J.H. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from l-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain 1993, 116(Pt 6):1425-1450.
54. Foster A.C., White R.J., Schwarcz R. Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J Neurochem 1986, 47:23-30.
55. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991, 56:2007-2017.
56. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011, 10:83-98.
57. Wexler N.S., Lorimer J., Porter J., Gomez F., Moskowitz C., Shackell E., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004, 101:3498-3503.
58. Guidetti P., Luthi-Carter R.E., Augood S.J., Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 2004, 17:455-461.
59. Jauch D., Urbanska E.M., Guidetti P., Bird E.D., Vonsattel J.P., Whetsell W.O., et al. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci 1995, 130:39-47.
60. Heyes M.P., Saito K., Crowley J.S., Davis L.E., Demitrack M.A., Der M., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115(Pt 5):1249-1273.
61. Guidetti P., Bates G.P., Graham R.K., Hayden M.R., Leavitt B.R., MacDonald M.E., et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 2006, 23:190-197.
62. Mazarei G., Neal S.J., Becanovic K., Luthi-Carter R., Simpson E.M., Leavitt B.R. Expression analysis of novel striatal-enriched genes in Huntington disease. Hum Mol Genet 2010, 19:609-622.
63. Stoy N., Mackay G.M., Forrest C.M., Christofides J., Egerton M., Stone T.W., et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 2005, 93:611-623.
64. Forrest C.M., Mackay G.M., Stoy N., Spiden S.L., Taylor R., Stone T.W., et al. Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease. J Neurochem 2010, 112:112-122.
65. Sathyasaikumar K.V., Stachowski E.K., Amori L., Guidetti P., Muchowski P.J., Schwarcz R. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease. J Neurochem 2010, 113:1416-1425.
66. Bjorkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008, 205:1869-1877.
67. Silvestroni A., Faull R.L., Strand A.D., Moller T. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 2009, 20:1098-1103.
68. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007, 130:1759-1766.
69. Gulaj E., Pawlak K., Bien B., Pawlak D. Kynurenine and its metabolites in Alzheimer's disease patients. Adv Med Sci 2010, 55:204-211.
70. Bonda D.J., Mailankot M., Stone J.G., Garrett M.R., Staniszewska M., Castellani R.J., et al. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep 2010, 15:161-168.
71. Schwarz M.J., Guillemin G.J., Teipel S.J., Buerger K., Hampel H. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. Eur Arch Psychiatry Clin Neurosci 2013, 263:345-352.
72. Guillemin G.J., Brew B.J., Noonan C.E., Takikawa O., Cullen K.M. Indoleamine 2,3-dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 2005, 31:395-404.
73. Guillemin G.J., Smythe G.A., Veas L.A., Takikawa O., Brew B.J. A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 2003, 14:2311-2315.
74. Yamada A., Akimoto H., Kagawa S., Guillemin G.J., Takikawa O. Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. J Neurochem 2009, 110:791-800.
75. Lue L.F., Rydel R., Brigham E.F., Yang L.B., Hampel H., Murphy G.M., et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001, 35:72-79.
76. Akimoto H., Yamada A., Takikawa O. Up-regulation of the brain indoleamine 2,3-dioxygenase activity in a mouse model of Alzheimer's disease by systemic endotoxin challenge. Int Cong Ser 2007, 1304:357-361.
77. Rahman A., Ting K., Cullen K.M., Braidy N., Brew B.J., Guillemin G.J. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS ONE 2009, 4:e6344.
78. Widner B., Leblhuber F., Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm 2002, 109:181-189.
79. Ogawa T., Matson W.R., Beal M.F., Myers R.H., Bird E.D., Milbury P., et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 1992, 42:1702-1706.
80. Giorgini F., Guidetti P., Nguyen Q., Bennett S.C., Muchowski P.J. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005, 37:526-531.
81. Campesan S., Green E.W., Breda C., Sathyasaikumar K.V., Muchowski P.J., Schwarcz R., et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 2011, 21:961-966.
82. Zwilling D., Huang S.Y., Sathyasaikumar K.V., Notarangelo F.M., Guidetti P., Wu H.Q., et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:863-874.
83. Amaral M., Outeiro T.F., Scrutton N.S., Giorgini F. The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease. J Mol Med (Berl.) 2013, 91:705-713.
84. Rover S., Cesura A.M., Huguenin P., Kettler R., Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 1997, 40:4378-4385.
85. Samadi P., Gregoire L., Rassoulpour A., Guidetti P., Izzo E., Schwarcz R., et al. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys. Mov Disord 2005, 20:792-802.
86. Beconi M.G., Yates D., Lyons K., Matthews K., Clifton S., Mead T., et al. Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048. Drug Metab Dispos 2012, 40:2297-2306.
87. Wild E.J., Tabrizi S.J. Targets for future clinical trials in Huntington's disease: what's in the pipeline?. Mov Disord 2014, 29:1434-1445.
88. Toledo-Sherman L.M., Prime M.E., Mrzljak L., Beconi M.G., Beresford A., Brookfield F.A., et al. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease. J Med Chem 2015, 58:1159-1183.
89. Giorgini F., Huang S.Y., Sathyasaikumar K.V., Notarangelo F.M., Thomas M.A., Tararina M., et al. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem 2013, 288:36554-36566.
90. Amaral M., Levy C., Heyes D.J., Lafite P., Outeiro T.F., Giorgini F., et al. Structural basis of kynurenine 3-monooxygenase inhibition. Nature 2013, 496:382-385.
91. van der Goot A.T., Zhu W., Vazquez-Manrique R.P., Seinstra R.I., Dettmer K., Michels H., et al. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc Natl Acad Sci U S A 2012, 109:14912-14917.
92. Yu C.J., Zheng M.F., Kuang C.X., Huang W.D., Yang Q. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2,3-dioxygenase activity in vitro. J Alzheimers Dis 2010, 22:257-266.
93. Yu D., Tao B.B., Yang Y.Y., Du L.S., Yang S.S., He X.J., et al. The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease. J Alzheimers Dis 2015, 43:291-302.
94. Mazarei G., Budac D.P., Lu G., Lee H., Moller T., Leavitt B.R. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain. Exp Neurol 2013, 249:144-148.